Anterior mitral leaflet modification to prevent left ventricular outflow tract obstruction during transcatheter mitral valve replacement: the PROTECT-LVOT registry
EuroIntervention · 2026-11 · 22 (22) · 1218-1227
DOI: 10.4244/eij-d-26-00822 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift EuroIntervention, 2026-11. Verfasst von Andrea Ruberti und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Hospital of Bellvitge, Barcelona, Spain. Hauptthemen laut MEDLINE: Transcatheter Mitral Valve Replacement, Ventricular Outflow Obstruction, Left, Mitral Valve, Ventricular Outflow Obstruction. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Left ventricular outflow tract (LVOT) obstruction remains the major limitation of transcatheter mitral valve replacement (TMVR). Anterior mitral leaflet (AML) modification has emerged as a key preventive strategy, yet real-world data remain limited and residual risk is still unknown. AIMS: We sought to evaluate the outcomes of TMVR with concomitant AML modification across valve-in-mitral annular calcification (ViMAC), valve-in-ring (ViR), and valve-in-valve (ViV) substrates. METHODS: We established a multicentre retrospective registry of consecutive patients undergoing TMVR with AML modification between 2017 and 2025. The co-primary in-hospital safety endpoint was a composite of cardiovascular death, stroke/transient ischaemic attack, and major bleeding. RESULTS: A total of 55 patients were included (67% females). The median age was 78 years (interquartile range [IQR] 73-81); the median Society of Thoracic Surgeons Predicted Risk of Mortality was 6.7% (IQR 4.8-9.5). AML modification was performed in 65.5% of cases with the Laceration of the Anterior Mitral leaflet to Prevent Outflow ObstructioN technique and in 34.5% with the Balloon-Assisted Translocation of the Mitral Anterior Leaflet technique. AML modification was successful in 96.4% of cases. Despite successful AML modification, haemodynamically significant LVOT obstruction occurred in 12.7% of cases. The co-primary in-hospital safety endpoint occurred in 20.0% of patients, driven by cardiovascular death in 14.5% of patients. Overall in-hospital mortality was 16.4%. The ViMAC substrate was associated with the numerically highest LVOT obstruction rate (ViMAC 20.7%, ViR 0.0%, ViV 8.3%, odds ratio [OR] 4.72, 95% confidence interval [CI]: 0.89-47.86; p=0.070). The aortomitral angle showed a borderline association with LVOT obstruction (OR 1.22 per degree, 95% CI: 0.99-1.48; p=0.059). CONCLUSIONS: AML modification enables TMVR in high-risk anatomies with high feasibility but does not eliminate LVOT obstruction. ViMAC represents the most challenging substrate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Cardiology, University Hospital of Bellvitge, Barcelona, Spain.
- Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain.
- BIO-HEART Group, Institut d'Investigació Biomèdica (IDIBELL), Barcelona, Spain.
- Department of Cardiology, Inselspital, University of Bern, Bern, Switzerland.
- Department of Cardiology, University Hospital of Vall d'Hebron, Barcelona, Spain.
- Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.
Zitieren
APA
Ruberti, A., Praz, F., Martí, G., De Backer, O., Amat-Santos, I., Estevez-Loureiro, R., Garot, P., Rudolph, V., Sabaté, M., Echarte-Morales, J., Roura, G., Comin, J., Gercek, M., Muntané-Carol, G., Gómez-Lara, J., Occhipinti, G., Basile, M., Gomez-Hospital, J. A., Angellotti, D., …, & Romaguera, R. (2026). Anterior mitral leaflet modification to prevent left ventricular outflow tract obstruction during transcatheter mitral valve replacement: the PROTECT-LVOT registry. EuroIntervention, 22(22), 1218-1227. https://doi.org/10.4244/eij-d-26-00822
Vancouver
Ruberti A, Praz F, Martí G, De Backer O, Amat-Santos I, Estevez-Loureiro R, et al. Anterior mitral leaflet modification to prevent left ventricular outflow tract obstruction during transcatheter mitral valve replacement: the PROTECT-LVOT registry. EuroIntervention. 2026;22(22):1218-1227. doi:10.4244/eij-d-26-00822
BibTeX
@article{Ruberti2026,
author = {Ruberti, Andrea and Praz, Fabien and Martí, Gerard and De Backer, Ole and Amat-Santos, Ignacio and Estevez-Loureiro, Rodrigo and Garot, Philippe and Rudolph, Volker and Sabaté, Manel and Echarte-Morales, Julio and Roura, Gerard and Comin, Josep and Gercek, Muhammed and Muntané-Carol, Guillem and Gómez-Lara, Josep and Occhipinti, Giovanni and Basile, Mattia and Gomez-Hospital, Joan A and Angellotti, Domenico and Akodad, Myriam and Regazzoli, Damiano and Martin, Pedro and Moreno, Raúl and Regueiro, Ander and Romaguera, Rafael},
title = {Anterior mitral leaflet modification to prevent left ventricular outflow tract obstruction during transcatheter mitral valve replacement: the PROTECT-LVOT registry},
journal = {EuroIntervention},
year = {2026},
volume = {22},
number = {22},
pages = {1218--1227},
doi = {10.4244/eij-d-26-00822}
}
EUVIMED